Immunocore Holdings plc (NASDAQ:IMCR) Given Average Recommendation of “Moderate Buy” by Brokerages

Immunocore Holdings plc (NASDAQ:IMCRGet Free Report) has been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $81.85.

A number of research analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $81.00 price target on shares of Immunocore in a research note on Monday, June 3rd. SVB Leerink began coverage on shares of Immunocore in a research report on Monday, April 29th. They set an “outperform” rating and a $74.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Wednesday, June 5th. Canaccord Genuity Group increased their price objective on shares of Immunocore from $63.00 to $67.00 and gave the stock a “hold” rating in a research report on Thursday, May 9th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $87.00 price target (up from $85.00) on shares of Immunocore in a report on Thursday, February 29th.

Get Our Latest Analysis on IMCR

Immunocore Price Performance

Shares of IMCR opened at $35.93 on Wednesday. Immunocore has a 1-year low of $35.03 and a 1-year high of $76.98. The stock has a market cap of $1.80 billion, a PE ratio of -29.45 and a beta of 0.83. The company has a debt-to-equity ratio of 1.22, a current ratio of 5.96 and a quick ratio of 5.94. The firm has a fifty day moving average price of $50.27 and a 200 day moving average price of $60.93.

Immunocore (NASDAQ:IMCRGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). The business had revenue of $70.30 million during the quarter, compared to analyst estimates of $70.72 million. Immunocore had a negative net margin of 22.60% and a negative return on equity of 16.54%. The company’s revenue for the quarter was up 27.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.35) earnings per share. As a group, sell-side analysts anticipate that Immunocore will post -1.88 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Tidal Investments LLC acquired a new position in Immunocore during the 1st quarter valued at about $423,000. Janus Henderson Group PLC raised its holdings in shares of Immunocore by 45.8% during the first quarter. Janus Henderson Group PLC now owns 257,080 shares of the company’s stock valued at $16,711,000 after acquiring an additional 80,748 shares during the period. Nan Fung Group Holdings Ltd purchased a new position in Immunocore during the first quarter valued at approximately $439,000. Orion Portfolio Solutions LLC grew its position in Immunocore by 33.7% during the first quarter. Orion Portfolio Solutions LLC now owns 23,127 shares of the company’s stock valued at $1,503,000 after purchasing an additional 5,826 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Immunocore by 86.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 342,000 shares of the company’s stock worth $22,230,000 after acquiring an additional 158,455 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.

Immunocore Company Profile

(Get Free Report

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

Recommended Stories

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.